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Chronic thromboembolic pulmonary hypertension (CTEPH) is thought to result from incomplete resolution of pulmon-
????????????????????????????????????????????????????????????????????????? ??????????????????????????????????? ??????
arterial lumina with collagenous obstructions. The treatment of choice is pulmonary endarterectomy (PEA) with low 
post-operative mortality and good long-term survival in expert hands. Patients ineligible for PEA or who have recurrent 
or persistent pulmonary hypertension after surgery have been previously the “Untreatable”. Modern CTEPH man a-
gement has now a solution for those previous no-option patients: balloon pulmonary angioplasty (BPA), and targeted 
medical therapies. Riociguat has been approved for inoperable CTEPH, and persistent-recurrent PH after PEA, and 
??????????????????????????????????? ????? ?????????????????????? ??????????????????????????????????????????????????
report that BPA improves haemodynamic, symptoms and functional capacity in patients with CTEPH, but controlled 
trials with long-term follow-up are needed. Complications include haemoptysis, wire injury, vessel dissection, vessel 
???????????????????????? ????????????????? ???????????????????????????????????????????????????????????????????
review summarises available evidence for PEA, BPA, and medical therapy, patient selection, peri-procedural imaging 
???????????????????????????????????????????????????????????????????????????????????????????
Introduction
Chronic thromboembolic pulmonary hypertension 
(CTEPH) is a rare disease of the pulmonary vascula-
ture which is classified as a distinct entity (Group 4) of 
pulmonary hypertension (PH) (1). CTEPH is believed to 
develop when a pulmonary embolism does not resolve 
and transforms into fibrous tissue that occludes major 
pulmonary arteries. A concomitant small-vessel arte-
riopathy plays an important role in the development of 
persistent PH after surgical pulmonary endarterectomy 
(PEA) and survival.
Early diagnosis and treatment by a multidisciplinary 
team are essential. Screening is based on ventilation/
perfusion lung scanning, and diagnosis is made by 
imaging typical CTEPH lesions with angiography, best 
by invasive digital subtraction angiography or direct in-
jection. Computed tomography is emerging to provide 
Take-home message:
????? ?????????? ?????????? ?????? ???????????????????????????????????????????????????? ????? ????????????? ???
??????????????????????????????????????????????????? ????????????????????????????????? ???????????????????????
????????????????????????????????????????????????????????????????????????????????????????????????????
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similar quality images as invasive angiography in the 
future, including parenchymal lung images as well as 
images of the heart and the great vessels for differen-
tial diagnoses. The CTEPH team should then address 
the question whether the gold-standard treatment PEA 
as a potentially curative intervention is feasible with an 
in-hospital mortality rate <5%. About 40-50% of patients 
with CTEPH is no surgical candidates or cannot un-
dergo surgery at an acceptably low in-hospital morta-
lity rate, and 17–31% of patients after PEA experience 
persistent/recurrent PH. Modern CTEPH management 
has now a solution for those previous no-option patients: 
balloon pulmonary angioplasty can be performed, and 
targeted medical therapies can be given.
Pulmonary Endarterectomy –  
An old technique newly stimulated
PEA remains the gold standard treatment with the op-
tion of potential cure with mortality rates as low as 2% 
in specialised centers ????????? (1, 2). Elligibility for PEA 
should be determined by a CTEPH team consisting of 
surgeons, PH specialists, radiologists and interven-
tionists. Tradionally, PEA was limited to patients with 
proximal disease and localisation of most proximal clot 
has been the main determinant of PEA eligibility (2, 3). 
Experienced centers have advanced their skills to allow 
surgical treatment for patients with more distal dis ease 
(4). Moreover, there is a growing understanding that 
PEA may lead to RV afterload reduction even in patients 
with high PVR and distal disease, in combination with 
other treatments (2).
Peri-procedural complications include stroke, bleeding, 
arrhythmia, pericardial and pleural effusions and 
post-operative reperfusion pulmonary edema (5). Re-
perfusion edema occurs in 5–20% of patients, espe-
cially in patients with high pre-operative pulmonary 
pressure (2, 6, 7). When supportive treatment with me-
chanical ventilation, diuresis and drugs approved for 
PAH are not enough, ECMO may be indicated (2, 8, 
9). ECMO both intra and post-operative has become 
standard of care in centers performing high-risk PEA 
(2, 8, 9).
Pre- and post-operative PVR, pulmonary vasoreacti-
vity, as well as age, comorbidities and functional status 
are factors assisting in the prediction of post-operative 
outcomes (10, 11, 12).
Persistent/recurrent PH after PEA is a major deter-
minant of poor prognosis and functional capacity for 
CTEPH patients undergoing PEA (7, 13). According to 
the European registry, 16.7% of patients are diagnosed 
with persistent/recurrent PH after PEA (14). The abil i-
ty to predict which patients are prone to develop such 
condition is of major practical importance. A concomi-
tant secondary microvasculopathy in addition to major 
pulmonary artery obstruction has been suggested as 
one of the mechanisms leading to persistent/recurrent 
PH after PEA (2). Recently Gerges et al. have con-
firmed the role of preoperative pulmonary artery pres-
TABLE 1. Reported effects of PEA, BPA and medical treatments in CTEPH
Treatment Source Year of 
publication
Number 
of  
patients
Change 
in 6MWD 
(*)
Change 
in PVR 
(*)
Change 
in mPAP 
(*)
Peripro-
cedural 
mortality
PEA Italian registry (39) 2016 554 41% –71% –48% 8.50%
French reference center (40) 2018 150 29% –60% –41% 2.90%
San Diego Health center (41) 2012 500 – –64% –43% 2.20%
United Kingdom National Cohort 
(42) 
2016 880 36% –62% –43% 2.4%**
German registry –  
Bad Nauheim (43) 
2017 236 – – – 2.50%
European CTEPH registry (6) 2011 386 – –66% – 4.60%
BPA French reference center (29) 2019 184 11% –45% –28% 2.20%
Hannover & Bad Nauheim (44) 2017 56 9% –26% –18% 1.80%
Japanese multicenter registry (36) 2017 308 35% –66% –48% 2.60%
Riociguat CHEST 1 (19) 2013 261 13% –31% –9% –
Bosentan BENEFiT (21) 2008 157 0% –24% –5% –
Macitentan MERIT–1 (23) 2017 80 10% –16% –4% –
Treprostinil SC CTREPH (25) 2019 105 15% –34% –7% –
Oral  
combinations***
(45) 2018 117 13% –41% –13% –
*for PEA – change is from pre procedure to post, BPA: baseline to completion of treatments, medications – change after 4–6 months of treatment. **30 day 
mortality rate for second half of the cohort. ***(ERAs+ PDE–5i/Riociguat). PEA: pulmonary endarterectomy, BPA: balloon pulmonary angioplasty, SC: subcu-
tan, 6MWD: 6 minute walk distance, PVR: pulmonary vascular resistance, mPAP: mean pulmonary artery pressure
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sure waveform analysis to predict secondary microvas-
culopathy and outcomes prior to PEA (15).
Advances in Medical Treatments for CTEPH
The initial step in the management of CTEPH is appro-
priate anticoagulation. Current guidelines suggest that 
effective anticoagulation over at least 3 months should 
precede a CTEPH diagnosis. 3 months is the minimal 
guideline-recommended treatment duration for acute 
pulmonary embolism. Furthermore, guidelines advise 
to continue lifelong anticoagulation to prevent recur-
rent thrombosis. While there are no large randomized 
trials regarding the preferable type of anticoagulation 
for CTEPH patients, recent registries point to benefi-
cial effects of Vitamin K antagonists as compared with 
DOACs (16), despite greater safety of direct oral an-
ticoagulants (DOACs) (17). Post-PEA functional and 
hemodynamic outcomes appeared unaffected by an-
ticoagulant choice. Bleeding events were similar, but 
recurrent VTE rates were higher in patients receiving 
DOACs (16).
Medical treatment for CTEPH patients is required in 
many patients, particularly in those who are no can-
didates for PEA because of distal location of vascular 
disease, or because they carry an unfavorable risk-be-
nefit ratio for major surgery. Furthermore, medical treat-
ments are considered for patients with severe hemody-
namic compromise prior to PEA or balloon pulmonary 
angioplasty (BPA), and after mechanical interventions 
in those with persistent/recurrent PH (18).
Riociguat was the first drug with clinical effectiveness 
to be approved for the treatment of inoperable CTEPH, 
or persistent/recurrent PH after PEA (19, 20). The drug 
is a stimulator of soluble guanylate cyclase (sGC) with 
both a direct effect and an indirect effect by sensitizing 
GC receptors to endogenous nitric oxide (NO). Impro-
ved exercise capacity (EC) and PVR were shown in the 
CHEST-1 and CHEST-2 trials (19).
The BENEFiT trial, (Bosentan Effects in iNopErable 
Forms of chronic Thromboembolic pulmonary hyper-
tension), a randomized, placebo-controlled trial with the 
Endothelin receptor antagonists (ERA) Bosentan did 
not meet the primary combined endpoint of 6MWD and 
decrease in PVR (21). Positive results where demon-
strated for the use of bosentan as bridging therapy be-
fore PEA (22). The MERIT-1 trial, examining the effect 
of macitentan in inoperable CTEPH showed improved 
PVR and 6MWD, however no change in WHO-FC (23). 
Actelion-Janssen has withdrawn their application for 
approval of macitentan for the treatment of CTEPH.
A significant advancement in medical treatment of 
CTEPH was made in the CTREPH trial, examining the 
effect and the safety of subcutaneous (SC) treprostinil 
for severe CTEPH (18, 24). Treprostinil treatment was 
evaluated for both inoperable CTEPH and per sistent/
recurrent PH after PEA. To ensure blinding of the study a 
high dose of the drug (uptitrated to 30 ng/kg/min) was 
compared with a low dose peaking at 5 ng/kg/min. About 
30% of patients were treated concomitantly with other 
PH related oral medications, such as riociguat, ERAs 
and PDE5 inhibitors. The study demonstrated signifi-
cant changes in 6MWD, hemodynamics and most sig-
nificantly, WHO-FC (18, 25). SC treprostinil, although 
not officially approved for the treatment of CTEPH, is 
used for patients who require medical treatment and 
can either not tolerate riociguat or are high-risk pati-
ents, defined by a low 6MWD and unfavorable hemody-
namic criteria such as a PVR > 800 and dynes.s.cm–5 
???????????????????????
Balloon pulmonary angioplasty – a new 
technique changing CTEPH
BPA treatment, first introduced in 2001 (26), is a per-
cutaneous balloon intervention breaking intralumi-
nal webs and bands without dissecting medial vessel 
layers. The procedure has been improved and refined 
over the years with better results and safety profiles, 
using a sequential approach with 4-7 sessions (27, 28). 
Mainly developed in Japan, the procedure is now intro-
duced and offered to European centers with favourable 
results (2, 29, 30, 31, 32). Current guidelines recom-
mend BPA for patients with either inoperable disease 
or those with unfavourable risk-benefit ratio for PEA (1). 
However, more and more centers are now offering this 
option to patients with persistent or recurrent PH after 
PEA surgery and in specific cases as combined treat-
ments, prior to, during or after PEA (33, 34).
In Japan BPA is preferred over PEA surgery. More and 
more data are collected regarding safety and effective-
ness (30), for example in the Euroeopan BPA Regist-
ry (NCT03245268). In a recent Japanese study, BPA 
alone or in combination with PEA has been shown to 
im prove prognosis when compared to patients treated 
with PEA alone or medical treatment alone (30). Survi-
val of inoperable patients diagnosed in the BPA era is 
better than previous (35).
BPA protocols vary from one center to the other, but re-
peat sessions are required. The main imaging assess-
ment used to assess the patients is pulmonary angio-
graphy, however CT scans, with 3D reconstructions 
and OCTs have provided important anatomic insights 
(2, 28). Routine use of OCT or IVUS during BPA has not 
been recommended.
According to a recent Japanese registry mPAP is re-
duced by about 20 mmHg to levels below 25 mmHg, 
with significant reduction in the need for other PH re-
lated medications and supplemental oxygen (36). The 
French BPA experience has documented improved 
hemo dynamics as well as improved 6MWD and NYHA 
functional class after 5.2 ± 2.4 BPA sessions. mPAP 
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has decreased by 26% and PVR by 43% when com-
pared to baseline values 29. BPA has also been shown 
to improve comorbidities such as metabolic function 
and renal function in parallel to improvement in pulmo-
nary hemodynamics (37).
Complication rates have been drastically reduced in re-
cent years with the use of balloons that have a smaller 
diameter than the lumen of the target vessel, ta pered 
balloons, soft wires, and a stepwise approach (2). 
Complications, including bleeding, wire-induced pul-
monary artery perforation and reperfusion edema oc-
cur in up to 10% of sessions however 30-day mortality 
is as low as 1-2% (2, 36, 28, 38, 29).
Future perspectives for CTEPH management
Despite all advances, there are still several challenges 
in CTEPH management that have to be faced. First, 
diagnosis remains hard and best accomplished if one 
thinks about CTEPH in the setting of major acute pul-
monary embolism. Machine learning algorithms are 
being developed to identify CTEPH cases as they pre-
sent under the clinical picture of acute PE in emergency 
rooms. Once diagnosed, the next step is the CTEPH 
team decision. Multidisciplinary teams face challen-
ges which are case-loads, logistics, and cost. Pati-
ent man agement is shifting from the simple question 
of PEA or no PEA to multimodality treatment choices 
????? ?????. Patients who were labelled inoperable may 
be found operable upon a second assessment (5). Pa-
tients who are inoperable or have persistent / recurrent 
PH post-surgery may benefit from a multitude of inter-
ventions including BPA, oral medical treatment in differ-
ent combinations and SC Treprostinil in severe cases 
(18). Treatment is increasingly individualised according 
to anatomical disease location, response to different 
treatments, personal preferences and treatment avail-
abilities.
Refined BPA is a safe and effective treatment option for 
patients with distal disease, patients with comorbidities, 
as well as patients with recurrent/persistent PH after 
surgery (14, 33, 34). Randomized studies will have to 
compare the role of BPA with PEA in suitable patients.
?????????????????????
???? ???? ?????????????? ????? ????? ?????????? ??????????
?????????? ???????????????? ???? ??????????????????
????? ?????????????????????????????????????????????????
???????????????????????????????????????????????????????????
???????? ???????????? ????????? ????????? ???????? ????
???????????????????????????????????????????????????? ??
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